ASTROCYTOMA, IDH-MUTANT, GRADE 3
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 3 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 3 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for brain tumor patients: targeted drug combo shows promise
Disease control Not yet recruitingThis study tests whether adding a targeted drug called vorasidenib to standard treatment (radiation and chemotherapy) can help people with a specific type of brain tumor (grade 3 astrocytoma with IDH mutation). About 408 participants will receive either vorasidenib or a placebo a…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New hope for brain cancer: immune booster and drug combo tested
Disease control Not yet recruitingThis study tests two drugs—retifanlimab (an immunotherapy that helps the immune system attack cancer) and DFMO (which slows tumor growth)—in people with progressive high-grade gliomas, aggressive brain tumors. The goal is to find the safest and most effective dose and see if the …
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:01 UTC